The Phase 3 study demonstrated the safety and non-inferiority of EuTYPH-C Inj.® Multi-dose compared to a World Health Organization (WHO) prequalified comparator TCV, Typbar TCV®. The vaccine was shown to be well-tolerated across all age groups with no serious adverse events.
The Phase 3 study confirmed that combining the RTS,S vaccine with antimalarial drugs reduces clinical malaria episodes, severe malaria cases, and deaths from malaria in young children by nearly two-thirds compared to either intervention alone. The vaccine-drug combination provided greater than 90% protection against malaria episodes.
PATH will lead an international collaboration to optimize Cry5B protein as an inexpensive, broad-spectrum antiparasitic treatment suitable for adults, children, and pregnant women. The goal is to expand anthelmintic MDA campaigns and reduce the global burden of STH infections.
The Washington COVID-19 biorepository has expanded its sample types to include convalescent plasma, enabling diagnostics developers to accelerate the development and validation of quality diagnostic products. This move aims to improve the performance of antibody assays and facilitate the verification of tests for global markets.
The Q-Plex Human Malaria Array measures multiple malaria antigens in a single sample, improving diagnosis sensitivity and supporting public health surveillance. This tool can help researchers develop more accurate RDTs and assess their performance.
A study published in PLOS ONE finds that lay provider HIV testing is an effective way to reach people at risk of HIV who have never been tested or test infrequently. The approach resulted in a high ART initiation rate of 91% and higher HIV positivity rates compared to facility-based testing.
A PATH study in Uganda found that self-administration of subcutaneous DMPA enables women to continue using injectable contraception longer than those receiving traditional injections. The study showed a 46% reduced risk of discontinuation among self-injecting women, with younger women benefiting most.
The World Health Organization has prequalified the India-made rotavirus vaccine ROTAVAC, which will be available for procurement by UN agencies and Gavi for use in low-resource countries. The vaccine is the result of a unique social innovation partnership between Indian and international researchers, public, and private sectors.
A novel drug delivery system using a microarray patch has been developed for HIV pre-exposure prophylaxis (PrEP), which could increase adherence among at-risk women and others. The patch contains tiny projections that painlessly deliver a drug, providing weeks or months of protection against infection.
The Serum Institute's rotavirus vaccine, ROTASIIL, demonstrated significant efficacy against severe rotavirus gastroenteritis, reducing severe diarrhea by over a third. The vaccine showed nearly 55% efficacy against the most severe cases, which can lead to dehydration, hospitalizations, and deaths.
A groundbreaking study in Uganda finds that self-injection of the Sayana Press contraceptive is both feasible and highly acceptable among women. The research suggests that this method can increase convenience and privacy for women seeking family planning options.
A new test accelerates global progress toward eliminating onchocerciasis, the leading cause of preventable blindness in Africa. The SD BIOLINE Onchocerciasis IgG4 rapid test is faster and easier to use than current options, providing results within 20 minutes.
A live attenuated ETEC vaccine candidate given with a novel adjuvant provided significant protection against disease, with a 58.5% efficacy rate against diarrhea of any severity. The vaccine also showed protective efficacy of 65.9% against severe ETEC diarrhea.
The India-developed rotavirus vaccine ROTAVAC has demonstrated excellent safety and efficacy in a Phase III clinical trial, reducing severe rotavirus diarrhoea by over half. The vaccine's impact extends beyond rotavirus infections, also showing protection against severe diarrhoea of any cause.
Studies in Mexico and Africa demonstrate a significant reduction in diarrheal disease deaths following rotavirus vaccine introduction. The findings highlight the importance of vaccination in reducing severe rotavirus infections among children in developing countries.
A pilot project by Voxiva and PATH aims to track and reduce Japanese encephalitis incidence through improved surveillance and response. The system uses phone and web-based technology to collect and analyze data, enabling health officials to respond quickly to reported cases and identify outbreaks.